ArticleCureus2025
Complete and Early Vitrectomy for Sterile Endophthalmitis After Bevacizumab: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravitreal anti-vascular endothelial growth factor injections are widely used for retinal disorders but may occasionally lead to sterile endophthalmitis, a condition that can be challenging to distinguish from infectious endophthalmitis. We describe a series of five patients who developed acute intraocular inflammation within 24-48 hours of receiving bevacizumab injections. These patients presented with decreased visual acuity and vitreous haze but reported minimal or no pain. All patients were managed urgently with pars plana vitrectomy according to the complete and early vitrectomy for endophthalmitis (CEVE) protocol, which included intraoperative antibiotic infusion and microbiological sampling. Cultures from the vitreous samples and the bevacizumab vial were negative. Following early vitrectomy, inflammation resolved in all patients, and visual acuity returned to baseline within 30 days. No postoperative complications were observed. None of the 38 additional patients who received injections from the same vial developed endophthalmitis. These findings support an immune-mediated, noninfectious mechanism for these cases and suggest that early vitrectomy within the CEVE framework promotes rapid resolution and favorable visual recovery. Continued vigilance and further research are warranted to refine management strategies for sterile endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.